Drug Profile


Alternative Names: [18F]-ML-10; ApoSense-PET; F-18-ML-10; ML-10

Latest Information Update: 16 Mar 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aposense
  • Developer Aposense; GlaxoSmithKline
  • Class Diagnostic agents; Imaging agents; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Suspended Brain metastases; Head and neck cancer; Lung cancer; Non-Hodgkin's lymphoma; Solid tumours; Stroke

Most Recent Events

  • 16 Mar 2016 Suspended - Phase-II for Brain metastases (Diagnosis) in Israel, USA (IV)
  • 16 Mar 2016 Suspended - Phase-II for Solid tumours, Lung cancer and Head and neck cancer (Diagnosis) in USA (IV)
  • 04 Jun 2015 GlaxoSmithKline terminates a phase II trial in Solid tumours (Diagnosis) in United Kingdom due to non-significant results (NCT01428440) before June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top